newsfilter
← Latest News
Business Wire·

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

$30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-linked Common Warrants Lineage Cell Therapeutics, Inc. (NYSE American and TASE: